OOIR: Observatory of International Research

Papers

(The H4-Index of Biodrugs is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond	339
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis	281
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis	122
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy	116
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making	99
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor	90
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome	90
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery	76
CAR-T Cells and the Kidney: Insights from the WHO Safety Database	60
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials	60
Acknowledgement to Referees	60
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart	45
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies	44
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022	40
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis	39
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?	36
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells	36
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review	35
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study	34
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer	33
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase	33
Progress and Challenges in the Treatment of Fabry Disease	33
Malaria Vaccines: Progress to Date	33
Interleukin-23 Inhibitors in Inflammatory Bowel Disease	32
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?	32

Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects	32
Acknowledgement to Referees	30
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series	30
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options	30
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review	29